The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, open-label phase II study of single-agent vintafolide versus vintafolide plus docetaxel versus docetaxel alone in second-line NSCLC patients with all target lesions expressing folate-receptor (TARGET).
Martin J. Edelman
Consultant or Advisory Role - Endocyte
Research Funding - Endocyte
Hong Ma
Employment or Leadership Position - Endocyte
Stock Ownership - Endocyte
Wendy Perez
Employment or Leadership Position - Endocyte
Stock Ownership - Endocyte
Alex A. Adjei
No relevant relationships to disclose
Nasser Hanna
Research Funding - Endocyte